Al San­drock makes his first post-Bio­gen move, join­ing turn­around ef­fort at a trou­bled gene ther­a­py start­up

A few years ago, when Bio­gen was look­ing for its next block­buster, the biotech re­port­ed­ly con­sid­ered buy­ing out Voy­ager Ther­a­peu­tics.

The deal made in­tu­itive sense …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER